Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2015 - 2026)

Axsome Therapeutics has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $713.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 19.6% year-over-year to $713.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 19.24% YoY) and the FY2025 annual result came in at $689.8 million, up 21.34% from the prior year.
• Liabilities and Shareholders Equity improved to $713.6 million in Q1 2026 per AXSM's latest filing, from $689.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $713.6 million in Q1 2026 and troughed at $88.6 million in Q1 2022.
• A 5-year average of $509.6 million and a median of $568.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity slumped 46.94% in 2022, then jumped 339.45% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $331.5 million in 2022, then jumped by 77.46% to $588.2 million in 2023, then slipped by 3.36% to $568.5 million in 2024, then advanced by 21.34% to $689.8 million in 2025, then climbed by 3.45% to $713.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $713.6 million, $689.8 million, and $669.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.